Synthesis of thienopyrimidine derivatives of expected anticancer activity / (Record no. 176389)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03723namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20251224125835.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 251201s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.19 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.19 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.04.M.Sc.2025.My.S |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Myrna Ashraf Mohamed Ali Farag, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Synthesis of thienopyrimidine derivatives of expected anticancer activity / |
| Statement of responsibility, etc. | by Myrna Ashraf Mohamed Ali Farag ; Supervision Prof. Dr. Manal Mostafa Hassan Kandeel, Prof. Dr. Asmaa Elsayed Abd El-Latief Kassab, Dr. Samar Ibrahim Mohamed Faggal. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | تشييد مشتقات الثينوبايريمدين ذات نشاط متوقع كمضادات للسرطان |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 54 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 52-54. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | This thesis comprises three chapters in addition to summaries in English and Arabic:<br/>The first chapter; General introduction which consists of a brief literature review of cancer disease and usage of anticancer drugs exerting their mechanism via VEGFR-2 inhibition. <br/>The second chapter; Review Article: Medicinal attributes of thienopyrimidine scaffolds incorporating aryl urea motif as potential anticancer candidates via VEGFR inhibition. <br/>The third chapter; Research Article: New thienopyrimidine-based derivatives: Design, synthesis, and biological evaluation as potent anticancer agents and VEGFR-2 inhibitors |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | تتألف هذه الرسالة من ثلاثة فصول، بالإضافة إلى ملخصين باللغتين الإنجليزية والعربية:<br/>الفصل الأول: مقدمة عامة تتضمن مراجعة للأبحاث المتعلقة بمرض السرطان واستخدام الأدوية المضادة للسرطان التي تمارس آليتها من خلال تثبيط مستقبل عامل نمو بطانة الأوعية الدموية 2 (VEGFR-2).<br/>الفصل الثاني: مقالة مرجعية: الخصائص الطبية لمشتقات الثينوبايريمدين التي تتضمن هيكل أريل يوريا كمرشحات محتملة لمكافحة السرطان من خلال تثبيط مستقبل عامل نمو بطانة الأوعية الدموية 2 (VEGFR).<br/>الفصل الثالث: مقالة بحثية: مشتقات جديدة قائمة على الثينوبايريمدين: التصميم والتشييد والتقييم البيولوجي كعوامل فعالة مضادة للسرطان ومثبطات مستقبل عامل نمو بطانة الأوعية الدموية 2 (VEGFR-2).<br/> |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmaceutical chemistry |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | الكيمياء الصيدلية |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Anticancer |
| -- | aryl urea |
| -- | synthesis |
| -- | thienopyrimidine |
| -- | VEGFR-2 |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Manal Mostafa Hassan Kandeel |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Asmaa Elsayed Abd El-Latief Kassab |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Samar Ibrahim Mohamed Fagga |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Manal Mostafa Hassan Kandeel |
| -- | Asmaa Elsayed Abd El-Latief Kassab |
| -- | Samar Ibrahim Mohamed Faggal |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmaceutical Organic Chemistry |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 01.12.2025 | 92660 | Cai01.08.04.M.Sc.2025.My.S | 01010110092660000 | 01.12.2025 | 01.12.2025 | Thesis |